The Debate Over Clopidogrel Continues
Genetics impacts how quickly people metabolize the commonly prescribed anti-clotting drug clopidogrel (Plavix), but whether genetics affects cardiovascular outcomes of people taking the drug is a subject of debate.
Read More
FDA Adds Boxed Warning to Plavix Label to Highlight Reduced Effectiveness of the Drug In Poor Metabolizers
The U.S. Food and Drug Administration (FDA) has updated the label information for the commonly used anti-clotting medication Plavix ® (clopidogrel) to stress to physicians that patients carrying certain genetic...
Read More
Medco to Include Genetics in Comparison of Anti-Clotting Drug Effectiveness
Medco Health Solutions, Inc., announced this week that it will conduct a clinical trial to assess whether clopidogrel bisulfate (Plavix ®, Bristol-Myers Squibb and Sanofi-aventis) is just as effective as...
Read More
More Evidence that Genetics Can Reduce the Efficacy of Anti-Clotting Medication Clopidogrel
A new report in the Journal of the American Medical Association adds to the mounting evidence that genetic variations impact the efficacy of clopidogrel (Plavix ®), a drug used to...
Read More
SNPwatch: Genetic Variants May Reduce Ability of Anti-Clotting Drug Clopidogrel to Prevent a Second Heart Attack
SNPwatch gives you the latest news about research linking various traits and conditions to individual genetic variations. These studies are exciting because they offer a glimpse into how genetics may...
Read More